Adenosine 2A Receptor Antagonism and AIH in ALS
Public ClinicalTrials.gov record NCT05377424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Acute Adenosine Receptor Antagonism to Promote Breathing Plasticity in ALS
Study identification
- NCT ID
- NCT05377424
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- University of Florida
- Other
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- Consume 20mg of istradefylline Drug
- Low Oxygen therapy Other
- Placebo counterpart to the istradefylline drug Drug
- SHAM counterpart to low oxygen therapy. Other
Drug · Other
Eligibility (public fields only)
- Age range
- 21 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2022
- Primary completion
- Jan 25, 2026
- Completion
- Aug 30, 2026
- Last update posted
- Mar 26, 2026
2022 – 2026
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical and Translational Research Building | Gainesville | Florida | 32610 | — |
| UF Health Jacksonville | Jacksonville | Florida | 32209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05377424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05377424 live on ClinicalTrials.gov.